Prostac: A New Composite Score With Potential Predictive Value in Prostate Cancer

Area of Science:

• Oncology
• Biomarkers
• Diagnostic Tools

Background:

• Prostate cancer (PCa) is a leading cancer diagnosis globally.
• Current diagnostic methods like PSA assays have limitations, including low specificity and sensitivity.
• Unnecessary biopsies lead to complications, highlighting the need for improved diagnostic accuracy.

Purpose of the Study:

• To develop a novel composite score, Prostac, for enhanced prostate cancer diagnosis.
• To identify and utilize specific Plasmacytoma Variant Translocation 1 (PVT1) biomarkers for PCa detection.

Main Methods:

• Developed a composite score (Prostac) using three PVT1 biomarkers (exons 4A, 4B, and 9).
• Employed real-time quantitative polymerase chain reaction (qPCR) for copy number analysis.
• Utilized a supervised learning algorithm (support vector machines) to create a classification hyperplane.

Main Results:

• PVT1 biomarkers were found to be significantly overexpressed in PCa epithelial cells.
• The Prostac score demonstrated linear separability for PCa biomarkers.
• Cross-validation showed 100% accurate classification of PCa cells.

Conclusions:

• The Prostac score shows significant promise for accurate prostate cancer diagnosis.
• This novel biomarker composite score could reduce the need for unnecessary biopsies.
• Further clinical trials are warranted to validate Prostac in patient populations.